Galapagos NV
ISIN: BE0003818359 | Ticker: GLPG | LEI: 549300QKJ78IY0IOV655
Country: Belgium
We are a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Year founded1999
Served areaWorldwide
HeadquartersGeneraal De Wittelaan L11 A3, 2800 Mechelen, Antwerpen – Belgium
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 21.12.23 | Guenter Peter | Board | Buy | EUR 23,069.75 |
| 21.12.23 | Baker Daniel George | Board | Buy | EUR 22,736.24 |
| 21.12.23 | Schaffert Susanne Antonie | Board | Buy | EUR 12,896.14 |
| 21.12.23 | Sturge Simon John | Board | Buy | EUR 6,448.07 |
| 28.08.23 | Manto Michele | Board | Buy | EUR 0.00 |
| 25.08.23 | Missotten Annelies | Board | Buy | EUR 89,284.00 |
| 07.07.23 | Missotten Annelies | Board | Buy | EUR 0.00 |
| 08.05.23 | Stoffels IMC | Board | Buy | EUR 0.00 |
| 06.05.23 | Filius Bart | Board | Other | EUR 51,662.16 |
| 06.05.23 | Manto Michele | Board | Other | EUR 21,774.96 |
| Position Holder | Short Interest in Percent | Date |
|---|---|---|
| Qube Research & Technologies Ltd. | 0.50% | 18.09.23 |
| Arrowstreet Capital, Limited Partnership | 0.51% | 27.04.23 |
| Total | 1.01% |
BE0003818359
LEI549300QKJ78IY0IOV655
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryBEL20
Main Stock ExchangeKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.